Dokl Biochem Biophys, 2022, 507(1):380-382

Subpopulation Heterogeneity of NK Cells during the Genetic Modification for Subsequent Use in Targeted Therapy

Obtaining genetically engineered NK cells is a developing area of immunotherapy. In this work, we analyzed the subset heterogeneity of NK cells subjected to retroviral transduction, taking into account the content of adaptive NK cell progenitors. It was shown that subsets KIR2DL2/DL3, as well as CD57KIR2DL2/DL3NKG2C, can be modified with greater efficiency than the corresponding subsets that do not carry the KIR2DL2/DL3 and NKG2C markers. After genetic modification, the CD57KIR2DL2/DL3NKG2C cells began to express CD57 de novo, acquiring the adaptive NK cell phenotype.

Streltsova MA, Boyko AA, Ustiuzhanina MO, Palamarchuk AI, Alekseeva NA, Velichinskii RA, Vavilova JD, Grechikhina MV, Sapozhnikov AM, Deev SM, Kovalenko EI

Department of immunology, Laboratory of cell interactions, Laboratory of molecular immunology, Department of Genomics of Adaptive Immunity, Laboratory of immunosequencing methods

: 10.1134/S1607672922340142
Scopus: 2-s2.0-85148093669
: 36787007
IBCH: 10558
Ссылка на статью в журнале: https://link.springer.com/10.1134/S1607672922340142
Нет данных о цитировании
Данные статьи проверены модераторами 2023-02-19

Список научных проектов, где отмечена публикация

  1. Development of means of prevention and treatment of COVID-19 and concomitant infectious diseases using genetic technologies (September 28, 2021 — December 31, 2023). Gabibov A.G., Andreev D.E., Aralov A.V., Bezuglov V.V., Belogurov A.A., Vodovozova E.L., Zvyagin A.V., Konstantinova I.D., Korshun V.A., Ovchinnikova T.V., Rubcov Y.P., Smirnov I.V., Tonevickiy A.G.. Agreement / contract, Ministry of Science.